Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Stock Information for Marker Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.